Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study

Table 2 Comparison of primary endpoints among different regimes

Therapeutic regimen	Median PFS	95% CI	P value	Median iPFS	95% CI	P value	Median ePFS	95% CI	P value
Group A	9.7 m	8.2–11.1	0.049	11.0 m	9.7–12.3	0.452	11.5 m	10.5–12.3	0.039
Group B	11.3 m	9.8–12.7	0.049	12.0 m	10.4–13.5	0.452	13.0 m	9.5–16.5	0.039
Group C	12.5 m	6.1–19.0	0.509	21.2 m	8.9–33.6	0.475	21.7 m	14.7–28.7	0.543
Group D	9.9 m	4.7–13.3	0.509	15.0 m	7.8–29.9	0.475	16.7 m	10.7–22.5	0.543
Group A + B	10.6 m	9.7–11.5	0.028	11.0 m	10.0-12.1	0.027	11.9 m	10.6–13.2	0.008
Group C + D	11.9 m	7.5–11.7	0.028	18.9 m	9.3–31.5	0.027	18.9 m	12.6–25.2	0.008

Note: Group A: 1st generation EGFR-TKIs monotherapy; Group B: 1st generation EGFR-TKIs + pemetrexed plus cisplatin/carboplatin chemotherapy; Group C: 1st generation EGFR-TKIs + bevacizumab; Group D: 1st generation EGFR-TKIs + pemetrexed plus cisplatin/carboplatin chemotherapy + bevacizumab
Abbreviations: ePFS, extracranial PFS; iPFS, intracranial PFS; PFS, progression-free survival; TKI, tyrosine kinase inhibitor

ISSN: 1471-2407